NanoViricides

Angela Harmantas, an Editor at Proactive with 15+ years in equity markets, specializes in junior resource stocks. Proactive provides global investment news, spanning finance hubs with bureaus in London, New York, Toronto, Vancouver, Sydney, and Perth. The team covers medium and small-cap markets, blue-chip companies, commodities, and emerging technologies. Proactive uses technology to enhance workflows, including automation and AI, while maintaining human authorship and editing.

NanoViricides filed its Annual Report for FY ending June 30, 2024, reporting $4.97M cash and $1.36M liabilities. Net cash used for operations, incl. NV-387 trials, was $6.31M. The company raised $3.12M via an At-the-Market offering and $1.53M post-period. Despite progress with NV-387 (efficacy against RSV, Influenza, MPOX, Smallpox, COVID), NanoViricides doubts its ability to continue operations through Sept 30, 2025, without additional funding.

Angela Harmantas, Editor at Proactive, has 15+ years in equity markets, focusing on junior resource stocks. Proactive provides global finance news, covering medium and small-cap markets, biotech, mining, and more. They use technology to enhance workflows, including AI, while maintaining human-authored content.

NanoViricides, Inc. reported its FY2024 financials, highlighting a cash balance of $4.97M, P&E assets of $7.5M, and current liabilities of $1.36M. The company raised $3.12M through an ATM offering and has $9.5M available for operations. Despite this, substantial doubt exists about its ability to fund planned objectives, including a Phase II trial for NV-387. NV-387, a broad-spectrum antiviral, showed potential in treating RSV, COVID, Influenza, and MPOX, with plans to advance it into Phase II trials.

NanoViricides filed its Annual Report, reporting $4.97M in cash, $7.5M in net property, and $1.36M in liabilities. The company used $6.31M for operations, including NV-387 Phase Ia/Ib trials, and raised $3.12M through an ATM offering. Despite this, substantial doubt exists about its ability to continue operations through September 2025. NV-387, a broad-spectrum antiviral, is advancing to Phase II trials for RSV and MPOX, with the company exploring non-dilutive funding and partnerships.

NanoViricides, Inc. updates on NV-387, a broad-spectrum antiviral drug mimicking host cells to disable viruses. Demonstrated effectiveness in animal trials against Influenza, COVID, RSV, and orthopoxviruses. Plans Phase II trials for human effectiveness, aiming for regulatory approval and market entry. Exploring collaborations to accelerate development.

NanoViricides, Inc. announced NV-387, a broad-spectrum antiviral agent using host-mimetic technology to target viruses like RSV, COVID-19, and Influenza. NV-387 mimics host cell landing sites, neutralizing viruses effectively. It has shown superior efficacy in animal studies, with a high safety profile in Phase I trials. The company is preparing for Phase II trials and aims for global regulatory approvals.

NanoViricides, Inc. introduces NV-387, a broad-spectrum antiviral nanomedicine using host-mimetic technology to combat viruses like RSV, COVID, and Influenza by mimicking host cell landing sites. NV-387 has shown superior efficacy in animal studies against various viruses, completed Phase I trials safely, and is advancing towards Phase II. It represents a potential breakthrough in antiviral treatment, aiming to address the challenge of virus mutation and resistance.

NanoViricides, a Phase II-ready company, develops antiviral drugs effective against emerging variants, notably NV-387, which shows broad antiviral activity against COVID-19, RSV, Influenza A, and orthopoxvirus, outperforming traditional treatments. NV-HHV-101, another candidate, is Phase I-ready for shingles treatment.

NanoViricides' NV-387 shows strong antiviral activity against coronaviruses, RSV, influenza A, including H5N1, and orthopoxviruses like Smallpox and Mpox. Phase 1 trials confirmed its safety, with plans to advance into Phase 2 for RSV. NV-387 outperformed existing drugs in animal models, indicating superior efficacy and potential for broad-spectrum antiviral treatment.